MedTrace Logo

Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

NCT07722754 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2026-07-23

No results posted yet for this study

Summary

Primary endpoint: objective response rate Secondary endpoints: PFS, OS and adverse events

Conditions

  • Colorectal Neoplasms Malignant
  • Neoplasm, Metastatic

Interventions

DRUG

Cetuximab

250mg/m\^2/week with a loading dose of 400mg/m\^2

DRUG

Irinotecan

125mg/m\^2 on D1 and D8 every three weeks

DRUG

Bevacizumab

7.5mg/kg every three weeks

DRUG

Sintilimab

200mg every three weeks

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Principal Investigators

  • Jian Xiao, MD · Guangdong Provincial People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2028-07-31
Completion
2029-01-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07722754 on ClinicalTrials.gov